Reference : Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Perit...
Scientific journals : Article
Human health sciences : Surgery
http://hdl.handle.net/2268/81973
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Carcinomatosis : Higher Complication Rate for Oxaliplatin Compared to Mitomycin C
English
Rouers, A. [> >]
Laurent, S. [> >]
Detroz, Bernard mailto [Centre Hospitalier Universitaire de Liège - CHU > > Chirurgie abdominale- endocrinienne et de transplantation >]
Meurisse, Michel mailto [Centre Hospitalier Universitaire de Liège - CHU > > Chirurgie abdominale- endocrinienne et de transplantation >]
2006
Acta Chirurgica Belgica
Acta Medica Belgica
106
302-306
Yes (verified by ORBi)
National
0001-5458
Bruxelles
Belgique
[en] Cytoreductive surgery ; hyperthermic intraperitoneal chemotherapy ; peritoneal carcinomatosis
[fr] colorectal cancer ; oxaliplatin ; mitomycin C.
[en] Peritoneal carcinomatosis (PC) from colo-rectal cancer carries a very poor prognosis with a
mean and median overall survival times of 6.9 and 5.2 months. It has been proved that a locoregional therapeutic
approach of this disease with cytoreduction followed by hyperthermic intraperitoneal chemotherapy (HIPEC) improved
survival of these patients. However, this combined treatment presents a high complication rate.
Methods : 21 patients with PC of colorectal origin underwent complete cytoreduction followed by HIPEC using
Mitomycin-C (13 patients) or oxaliplatin (8 patients) and the open coliseum technique. For each case the medical datas
were retrospectively analysed to determine feasibility, morbidity, mortality, survival time and prognostic factors.
Results : All patients presented a Sugarbaker’s Peritoneal Cancer index inferior to 15. The mean operating time was
453 minutes. After a median follow-up of 24.9 months, actuarial disease-free survival was 36.6% at 5 years. The median
survival time was 34 months. The morbidity rate was 33.3% with a significant higher complication rate in the oxaliplatin
group (5/8) than in the Mytomycin-C (MMC) group (2/13). One patient (4.7%) died two months after treatment
with MMC (endocarditis).
Conclusions : This series confirm positive impact of cytoreduction and HIPEC on PC. We obtained a moderated
complications rate thanks to a high degree of selection of the patient. Oxaliplatin scheme is responsible of a higher
morbidity than in MMC group. Phase III trial comparing these two drugs is needed.
Professionals ; Students ; General public
http://hdl.handle.net/2268/81973

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
rouers(1).pdfPublisher postprint66.7 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.